After Yang Ping established the "New Adjuvant" project team, across the ocean, in the United States, the meeting room of a company's strategic analysis department.
The enormous round floor-to-ceiling windows framed the city's skyline drawn by skyscrapers, with the indoor temperature consistently maintained at a comfortable 22 degrees Celsius, and the air purifier operating smoothly.
An internal briefing on global vaccine adjuvant research dynamics was being held.
The PPT on the large circular screen turned to a new page, titled "Monitoring Potential Technological Trends in the Asia-Pacific Region," with the basic information of Yang Ping's project team prominently displayed—a somewhat rudimentary list of members, along with somewhat youthful photos of Jiang Jitong, Chu Xiaoxiao, and others, and the highlighted "Five hundred million RMB (approximately seventy million USD) funding."
